Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

Enric Alvarez,1,2 Victor Perez,4,2 Francesc Artigas3,2 1Department of Psychiatry, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Institut de Recerca Biomedica Sant Pau, Barcelona, Spain; 2Ministry of Science and Innovation, CIBERSAM, Madrid, Spain; 3Institut d’Investigacions Bi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alvarez E, Perez V, Artigas F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/710e4150ec26410886ef62460f1d9d1d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:710e4150ec26410886ef62460f1d9d1d
record_format	dspace
spelling	oai:doaj.org-article:710e4150ec26410886ef62460f1d9d1d2021-12-02T00:19:37ZPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder1178-2021https://doaj.org/article/710e4150ec26410886ef62460f1d9d1d2014-07-01T00:00:00Zhttp://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-a17597https://doaj.org/toc/1178-2021 Enric Alvarez,1,2 Victor Perez,4,2 Francesc Artigas3,2 1Department of Psychiatry, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Institut de Recerca Biomedica Sant Pau, Barcelona, Spain; 2Ministry of Science and Innovation, CIBERSAM, Madrid, Spain; 3Institut d’Investigacions Biomediques de Barcelona, CSIC, Barcelona, Spain; 4Institut de Neuropsiquiatria I Adiccions, Universitat Autonoma de Barcelona, Hospital del Mar, Barcelona, Spain Abstract: Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concentration of serotonin, dopamine, and noradrenaline. Twelve clinical trials have been carried out, nine of which had positive results versus placebo. When active comparators were included in the study design, no significant differences were found except in one study in which the efficacy of vortioxetine was superior to the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors (SSRI)/serotonin–norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies indicate that the drug does not cause any important problems on blood tests, vital signs, or on electrocardiography. The lack of weight gain and induction of metabolic syndrome and the lack of significant changes in the QTc are especially important. The incidence rate of sexual dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains intact with vortioxetine. Keywords: depression, clinical trial, efficacyAlvarez EPerez VArtigas FDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1297-1307 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Alvarez E Perez V Artigas F Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
description	Enric Alvarez,1,2 Victor Perez,4,2 Francesc Artigas3,2 1Department of Psychiatry, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Institut de Recerca Biomedica Sant Pau, Barcelona, Spain; 2Ministry of Science and Innovation, CIBERSAM, Madrid, Spain; 3Institut d’Investigacions Biomediques de Barcelona, CSIC, Barcelona, Spain; 4Institut de Neuropsiquiatria I Adiccions, Universitat Autonoma de Barcelona, Hospital del Mar, Barcelona, Spain Abstract: Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concentration of serotonin, dopamine, and noradrenaline. Twelve clinical trials have been carried out, nine of which had positive results versus placebo. When active comparators were included in the study design, no significant differences were found except in one study in which the efficacy of vortioxetine was superior to the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors (SSRI)/serotonin–norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies indicate that the drug does not cause any important problems on blood tests, vital signs, or on electrocardiography. The lack of weight gain and induction of metabolic syndrome and the lack of significant changes in the QTc are especially important. The incidence rate of sexual dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains intact with vortioxetine. Keywords: depression, clinical trial, efficacy
format	article
author	Alvarez E Perez V Artigas F
author_facet	Alvarez E Perez V Artigas F
author_sort	Alvarez E
title	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
title_short	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
title_full	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
title_fullStr	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
title_full_unstemmed	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
title_sort	pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/710e4150ec26410886ef62460f1d9d1d
work_keys_str_mv	AT alvareze pharmacologyandclinicalpotentialofvortioxetineinthetreatmentofmajordepressivedisorder AT perezv pharmacologyandclinicalpotentialofvortioxetineinthetreatmentofmajordepressivedisorder AT artigasf pharmacologyandclinicalpotentialofvortioxetineinthetreatmentofmajordepressivedisorder
_version_	1718403807883296768

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

Ejemplares similares